Enterprise Value

-37.43M

Cash

258.9M

Avg Qtr Burn

-36.5M

Short % of Float

17.45%

Insider Ownership

3.18%

Institutional Own.

92.75%

Qtr Updated

08/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
NX-1607 Details
Solid tumor/s, Cancer

Phase 1

Data readout

NX-2127 (BTK degrader) Details
Non-Hodgkin lymphoma, Blood cancer, Cancer, B-cell malignancies, Chronic lymphocytic leukemia, Mantle cell lymphoma, Diffuse large B cell lymphoma

Phase 1

Data readout

NX-5948 Details
Cancer, B-cell malignancies

Phase 1

Data readout

NX-1607 + paclitaxel Details
Solid tumor/s, Cancer

Phase 1a

Data readout

DeTIL-0255 Details
Ovarian cancer, Cancer, Cervical cancer, Endometrial cancer

Failed

Discontinued